As expected, the reactive CD8+ T cell subset harbored the most frequent clonal expansion, and 44.3% of these cells were clonally expanded, suggesting that CD8+ TILs are major anti-tumor effector T cells in CTCL. The gene discussed is CD8A; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.